Clinical Trial: Iparomlimab and Tuvonralimab in HNSCC

U.S., July 30 -- ClinicalTrials.gov registry received information related to the study (NCT07090317) titled 'Iparomlimab and Tuvonralimab in HNSCC' on July 21.

Brief Summary: This study is a single center, non-randomized, prospective phase II clinical trial to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab in patients with with recurrent/metastatic head and neck squamous cell carcinoma failed second-line treatment. The participants would receive cetuximab combined with Iparomlimab and Tuvonralimab until termination criteria are met.

Study Start Date: July 31

Study Type: INTERVENTIONAL

Condition: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Intervention: DRUG: Iparomlimab and Tuvonralimab

The administr...